* history of hypersensitivity to canakinumab or to biologic drugs * intubated and on mechanical ventilation (invasive) at time of randomization * treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tnf inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis and corticosteroids (any route of administration) are permitted. * suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19

* history of hypersensitivity to canakinumab or to biologic drugs * intubated and on mechanical ventilation (invasive) at time of randomization * treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tnf inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis and corticosteroids (any route of administration) are permitted. * suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19

- history of hypersensitivity to canakinumab or to biologic drugs - intubated and on mechanical ventilation (invasive) at time of randomization - treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tnf inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis and corticosteroids (any route of administration) are permitted. - suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19

- history of hypersensitivity to canakinumab or to biologic drugs - intubated and on mechanical ventilation (invasive) at time of randomization - treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tnf inhibitors and anti-il-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. note: immunomodulators (topical or inhaled) for asthma and atopic dermatitis and corticosteroids (any route of administration) are permitted. - suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of covid-19